Ben Venue Consent Decree Could Be Signal on Hospira, Analyst Says

February 1, 2013

Boehringer Ingelheim subsidiary Ben Venue Laboratories has signed a consent decree to resolve a history of good manufacturing practice (GMP) slipups. The decree would let it continue making some essential drugs while a third party assesses its facilities — a provision analysts say could open the door to a similar decree for Hospira.

Ben Venue agreed to the consent decree without admitting or denying government allegations that it violated the 1938 FD&C Act.

Not only is the consent decree bad news for Ben Venue, it could also be a signal for Hospira as the issues at Ben Venue are “not that different,” RBC Capital Markets analyst Shibani Malhotra said.

Do yourself a favor and avoid costly mishaps when the FDA comes to inspect your facility by ordering your copy of Surviving an FDA Inspection Interview.

This instructional guide and DVD creates a powerful, hour-long training event that shows employees the types of questions and tactics they’ll face during inspection, and gives them the confidence to respond correctly. Don’t incur thousands of dollars in costs for a simple mistake you could have avoided, order your copies of this must-have today!